North Star Asset Management Inc. raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 587.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,556 shares of the medical research company’s stock after buying an additional 9,875 shares during the quarter. North Star Asset Management Inc.’s holdings in Amgen were worth $2,009,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Janus Henderson Group PLC grew its holdings in Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after buying an additional 3,601,087 shares during the period. FMR LLC grew its holdings in Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares during the period. Renaissance Technologies LLC grew its holdings in Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after buying an additional 986,700 shares during the period. BlackRock Inc. grew its holdings in Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares during the period. Finally, Nordea Investment Management AB grew its holdings in shares of Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after purchasing an additional 806,119 shares during the period. Institutional investors own 79.61% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.89 earnings per share. research analysts predict that Amgen, Inc. will post 13.24 earnings per share for the current year.
Amgen announced that its Board of Directors has authorized a stock buyback program on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.78%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 205.45%.
AMGN has been the subject of a number of research reports. Argus upgraded Amgen from a “hold” rating to a “buy” rating and boosted their target price for the stock from $192.33 to $220.00 in a report on Tuesday, January 23rd. Citigroup cut Amgen to a “neutral” rating in a report on Monday, December 18th. JPMorgan Chase & Co. reiterated a “hold” rating and set a $191.00 target price on shares of Amgen in a report on Sunday, February 4th. Goldman Sachs Group cut Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Finally, Mizuho set a $192.00 target price on Amgen and gave the stock a “buy” rating in a report on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $191.72.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.